12 completed, 2 not yet recruiting, 2 unknown, 1 active not recruiting. 18 Phase 4.
| Phase | Trials | Status |
|---|---|---|
| Phase 4 | 18 | Completed 12, Not yet recruiting 2, Unknown 2, Active not recruiting 1, Recruiting 1 |
Follow oxybutynin: new trials by email Literature Review of oxybutynin trials Research Report on oxybutynin
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Hormone thERapy Effects on BRAin-HEART Health During the Menopausal Transition Transdermal estradiol, Standard of care - non hormonal - Menopause, Perimenopause | Phase 4 | Not yet recruiting | McGill University Health Centre/Research Institute of the McGill University Health Centre | 100 | 2026-11-01 | 2026-07-29 |
| Effect of Oxybutynin on Opioid Use After Urologic Surgery in Children Oxybutynin, Placebo - Ureteropelvic Junction Obstruction, Hypospadias | Phase 4 | Not yet recruiting | University of Calgary | 200 | 2026-11-01 | 2026-11-02 |
| Endotype DIrected Treatment for OSA in Down Syndrome ato-oxy, Oxygen - Obstructive Sleep Apnea (OSA), Down Syndrome | Phase 4 | Recruiting | University of Arizona | 200 | 2026-03-14 | 2026-09-03 |
| Τhe Combination of Pharmacotherapy With RECOVERYTRSGR and RECOVERYTRSBDGR. Group A: (Clozapine, quietiapine, olanzapine, aripiprazole, zyprasidone, risperidone, asenapine, paliperidone, clopixol,anxiolytics: clonazepam, stedon, tavor antidepressants: seropram),, Group B (Pharmacotherapy and TAU) (Clozapine, quietiapine, olanzapine, aripiprazole, zyprasidone, risperidone, asenapine, paliperidone, clopixol, clonazepam, stedon, tavor, antidepressants,, Group C (Pharmacotherapy and Psychotherapy) Clozapine, quietiapine, olanzapine, aripiprazole, zyprasidone, risperidone, asenapine, paliperidone, clopixol, clonazepam, stedon, tavor, lithium, depakine - Treatment Resistant Schizophrenia, Treatment Resistant Bipolar Disorder | Phase 4 | Active not recruiting | Dr. Stavroula Rakitzi | 84 | 2025-06-04 | 2026-05-01 |
| Pharmacological Treatment Targeting Endotypic Traits of Obstructive Sleep Apnea Atomoxetine 80mg combined with oxybutynin 5mg, Venlafaxine 37.5mg, oxybutynin 5mg combined with trazodone 100mg - Obstructive Sleep Apnea of Adult | Phase 4 | Completed | China Medical University Hospital | 45 | 2024-11-05 | 2026-04-23 |
| Beta-3 Agonist and Anti-muscarinic Agent for Sjogren's Syndrome With Overactive Bladder mirabegron, oxybutynin, tolterodine, solifenacin - Sjogren's Syndrome, Overactive Bladder Syndrome | Phase 4 | Unknown | China Medical University Hospital | 50 | 2021-03-23 | 2021-08-10 |
| Inflammation in Women With Urgency Urinary Incontinence Treated With Anticholinergics Oxybutynin, Solifenacin, Tolterodine, Trospium, or Fesoterodine - Urinary Incontinence, Urgency Urinary | Phase 4 | Completed | Brigham and Women's Hospital | 20 | 2019-10-30 | 2022-11-15 |
| Flexibly adding-on Second Antimuscarinic Agent to the First Antimuscarinics for Refractory Overactive Bladder Syndrome Detrusitol 4mg QD and Oxybutynin ER 5mg QD, Detrusitol 4mg QD - Overactive Bladder | Phase 4 | Completed | Buddhist Tzu Chi General Hospital | 129 | 2013-03-01 | 2017-03-08 |
| Comparison of Solifenacin and Oxybutynin in the Treatment of Overactive Bladder Solifenacin, Oxybutynin - Overactive Bladder | Phase 4 | Unknown | Adana Numune Training and Research Hospital | 500 | 2011-09-01 | 2011-08-26 |
| Safety and Efficacy Evaluation of Oxybutynin Topical Gel In Children With Neurogenic Bladder Oxybutynin, Placebo - Overactive Detrusor, Neurogenic Bladder | Phase 4 | Completed | AbbVie | 52 | 2011-05-17 | 2024-09-04 |
| Use of Oxybutynin for Treating Hyperhidrosis: A Placebo-control Study Oxybutynin, placebo - Hyperhidrosis | Phase 4 | Completed | University of Sao Paulo | 50 | 2010-12-01 | 2011-09-22 |
| A Study to Compare Two Medications With an Inactive Medication and Look at the Effect on a Person's Mental Ability Solifenacin, Oxybutynin, Placebo - Cognition | Phase 4 | Completed | Astellas Pharma Inc | 26 | 2010-04-01 | 2012-10-15 |
| Efficacy of Oxybutynin in Paediatric Cystitis Oxybutynin, "Orasweet" Liquid Placebo, Antibiotics - Cystitis | Phase 4 | Completed | University of Calgary | 81 | 2008-10-01 | 2022-12-12 |
| Clinical Study of Solifenacin Succinate in Patients With Bladder Symptoms Due to Spinal Cord Injury or Multiple Sclerosis Solifenacin Succinate, Oxybutynin Hydrochloride, Placebo - Multiple Sclerosis, Neurogenic Bladder | Phase 4 | Completed | Astellas Pharma Inc | 249 | 2008-03-14 | 2024-11-14 |
| Efficacy of a Combined Surgical and Pharmacological Therapy to Treat Mixed Urinary Incontinence. TVT-O/Oxytrol, TVT-O, Oxytrol - Urinary Incontinence Mixed (Stress and Urge) | Phase 4 | Completed | Jewish General Hospital | 66 | 2007-10-01 | 2013-07-15 |
| Study to Compare the Safety and Efficacy of Solifenacin With Oxybutynin for the Treatment of Overactive Bladder (VECTOR) solifenacin, oxybutynin immediate release - Overactive Bladder | Phase 4 | Completed | Astellas Pharma Inc | 132 | 2006-12-01 | 2010-06-08 |
| A Study Evaluating Oxybutynin in Patients With Neurogenic Overactive Bladder Associated With a Neurological Condition Oxybutynin transdermal system - Detrusor Hyperreflexia | Phase 4 | Completed | Watson Pharmaceuticals | 24 | 2004-12-01 | 2010-04-30 |
| Safety and Efficacy Study of Transdermal Oxybutynin to Treat Overactive Bladder With a Neurological Condition Oxybutynin - Detrusor Hyperreflexia | Phase 4 | Completed | Watson Pharmaceuticals | 57 | 2004-12-01 | 2012-02-09 |
Urinary Bladder, Overactive (4) · Urinary Bladder, Neurogenic (2) · Cystitis (1) · Down Syndrome (1) · Hyperhidrosis (1) · Hypospadias (1) · Multicystic renal dysplasia, bilateral (1) · Multiple Sclerosis (1) · Pain, Postoperative (1) · Schizophrenia, Treatment-Resistant (1) · Sjogren's Syndrome (1) · Sleep Apnea, Obstructive (1) · Spinal Cord Diseases (1) · Urinary Incontinence (1) · Xerostomia (1)
Astellas Pharma Inc (3) · China Medical University Hospital (2) · University of Calgary (2) · Watson Pharmaceuticals (2) · AbbVie (1) · Adana Numune Training and Research Hospital (1) · Brigham and Women's Hospital (1) · Buddhist Tzu Chi General Hospital (1) · Dr. Stavroula Rakitzi (1) · Jewish General Hospital (1) · McGill University Health Centre/Research Institute of the McGill University Health Centre (1) · University of Arizona (1) · University of Sao Paulo (1)
United States (5) · Canada (3) · Taiwan (3) · United Kingdom (2) · Australia (1) · Belgium (1) · Brazil (1) · Czechia (1) · France (1) · Germany (1) · Greece (1) · Hungary (1) · Italy (1) · Netherlands (1) · Russia (1)
Gary Hoel, RPh, PhD (2) · Daniel Combs, MD (1) · Dr. Polyxeni Georgila, M. D. (1) · Dr. Stavroula Rakitzi, PhD (1) · Hann-Chorng Kuo, M.D. (1) · Murat Api, M.D., Ph.D. (1) · Vatche Minassian, MD, MPH (1)
PMID 19628264, PMID 19683731, PMID 20690893, PMID 21175373, PMID 23332882, PMID 37160401
2008 (1)